Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Apr 02, 2023 12:53pm
181 Views
Post# 35374687

RE:RE:Pharma faces looming patent cliff - seller's market in bio

RE:RE:Pharma faces looming patent cliff - seller's market in bioThanks, jimsenior, for your comments. I share your views. The results are too good to ignore or give up on.

Uber has driven me nuts for years. I think he is the former Vic, or runningman, who became the moderator of the Yahoo board in its current form. I called him out by name a few years ago for being so biased against the company and he said little in reply.

His main arguments against ONCY are that Pfizer has known about ONCY in the past and passed on it 15 years or so ago when it was proposed for pet cancer as a monotherapy., so they are now not really interested That makes no sense whatsoever given the huge expansion of knowledge, interest and clinical results regarding immuno-oncology in the last 6-8 years, and our specific results. He also derides the company for dilution. How are they supposed to make progress in developing their IP (a specific version of a wild virus) without keeping the company going? Would be all be better off if they had gone out of business 5 years ago? His other main beef is that Matt has too good a deal, and we should all resent him for it. Basically Matt had the good sense to pull together a team of advisors, build a good professional staff and partner with big pharma to get us to this stage.

None of what is said over there makes any sense. Armed is holding ONCY at about $10 a share. Tam is just a whiner who understands little about biotech or science, and thinks that careful management would have not taken so long, so they must be laze.

In sum, that board is a black hole of negativity. And if ONCY were still doing the same things it did when it was doing a H and N trial, it would readily be seen as a scam to pay the management a salary. But that is not at what is happening here. 
<< Previous
Bullboard Posts
Next >>